Otolaryngologists face many challenges while trying to fulfill our mission of providing outstanding healthcare. For example, there are not enough audiologists in the workforce to provide for all the auditory testing and rehabilitation needs of otolaryngology patients, let alone for the patients ofpediatricians, internists , neurologists, and others involved in the assessment of hearing and balance. Even if there were an unl imited number of audiologists,~conomic pressures have forced physicians to consider the cost-effectiveness of each allied health professional whom we employ. Similar concerns exist for evaluation of patients with balance disorders, voice disorders, and other maladies.
To address these problems, during the past several years the American Academy of Otolaryngology-Head and Neck Surgery has developed its Certificate Program for Otolaryngology Personnel (CPOP). The program was launched approximately 2 years ago, but many oto laryngologists remain unaware of its existence and its potential. PATA OL so lution provides optimal relief
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It is reasonable to anticipate that this experience will be duplicated in areas other than hearing assessment. As we strive to prov ide superior pat ient care, optim ize the time and use of our cert ified audiologists and speech-language pathol ogists, and remain economically viable, expanded use oftrained techn icians may prove to be a very effective strategy for otolaryngologic practic e in the 21st century.
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